News
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...
Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...
Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...
4don MSN
Sanofi reportedly halts sales of cholesterol drug Praluent in China amid limited availability
Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as surging demand has caused availability issues, Reuters reported on Tuesday, ...
Stocktwits on MSN5d
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback